Dravet Syndrome Indication Will Set GW Pharma Apart On US Epilepsy Market
GW Pharma is on track for 2017 filings for its marijuana-derived epilepsy therapy, Epidiolex (cannabidiol), following more positive data from the third Phase III study for the drug to be presented this year – however, Epidiolex's potential in Dravet syndrome will be its competitive edge to set GW apart from rivals.
You may also be interested in...
Safety and efficacy in study published in New England Journal of Medicine bode well for cannabinoid therapy Epidiolex, which is headed to FDA mid-year.
GW Pharmaceuticals has identified oncology as a potential new therapeutic area for its cannabinoid-based products, but such research is at an early stage and the UK company is currently focused on orphan neurology indications and the setting up commercial operations in the US and Europe.
Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.